Published in Genetics and Environmental Law Weekly, May 23rd, 2009
On April 29, 2009, after the market closed, Sequenom announced that the expected launch of its SEQureDxTM Down syndrome test will be delayed because of employee mishandling of SEQureDx test data and results. As a result, in after-market trading, Sequenom stock lost more than two-thirds of its trading value, falling from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.